Tomasz Zapolski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tomasz Zapolski has a total of 688 co-authors. Here are the top co-authors by number of shared publications:
Andrzej Wysokiński
Med Univ Lublin, Dept Cardiol, Ul Jaczewskiego 8, PL-20954 Lublin, Poland
24 shared publications- Andrzej Jaroszyński
Collegium Medicum, Jan Kochanowski University, 25-516 Kielce, Poland
14 shared publications - Anna Wysocka
Department of Internal Medicine and Internal Nursing, Faculty of Health Sciences, Medical University, Lublin, Poland
6 shared publications Andrzej Książek
Department of Nephrology, Medical University of Lublin, Lublin, Poland
5 shared publications- Andrzej P. Wysokiński
Department of Cardiology, Medical University of Lublin, Jaczewskiego 8, 20-954 Lublin, Poland
5 shared publications - Jacek Furmaga
Department of General and Transplant Surgery and Nutritional Treatment, Medical University of Lublin, Lublin, Poland
5 shared publications
Latest Publications
- Open Access
- 20 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (6) , 2832
BKPyV—Co-Architect of the Fate of a Renal Transplant During a One-Year Observation Period
To identify BKPyV, the VP1 protein sequence was analyzed and classified into genotypes in 246 RTRs before and after RTx from deceased donors during a one-year observation period. Quantitative assessment of BKPyV was conducted via qPCR. Prior to RTx, genotypes I and IV were identified in the urine (7.27 × 106; 1.20 × 105) and in serum (5.75 × 104; 1.12 × 104). After RTx, genotype I was predominant; identification of DNAuria-BKPyV (62.07%) and BKPyV-DNAemia (55.56%) peaked after three months, and the highest DNAuria-BKPyV titer was also observed after three months (6.48 × 109), whereas the BKPyV-DNAemia titer did not peak until after six months (2.21 × 107). The highest number of copies of genotype IV in the urine was observed after six months (9.54 × 109), while the highest titer in the serum was not observed until after 12 months (3.88 × 106). DNAuria-BKPyV precedes BKPyV-DNAemia, affects a larger group of patients, and has a greater and more easily detected viral load, which makes it not only an earlier marker, but the key predictive marker of greater clinical value than later detection of BKPyV-DNAemia alone. Early monitoring of DNAuria-BKPyV should be the basis of classical screening, and not merely an addition to it, and therapeutic interventions should be undertaken early to prevent nephropathy.
- 20 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (6) , 2832
Open AccessBKPyV—Co-Architect of the Fate of a Renal Transplant During a One-Year Observation Period
To identify BKPyV, the VP1 protein sequence was analyzed and classified into genotypes in 246 RTRs before and after RTx from deceased donors during a one-year observation period. Quantitative assessment of BKPyV was conducted via qPCR. Prior to RTx, genotypes I and IV were identified in the urine (7.27 × 106; 1.20 × 105) and in serum (5.75 × 104; 1.12 × 104). After RTx, genotype I was predominant; identification of DNAuria-BKPyV (62.07%) and BKPyV-DNAemia (55.56%) peaked after three months, and the highest DNAuria-BKPyV titer was also observed after three months (6.48 × 109), whereas the BKPyV-DNAemia titer did not peak until after six months (2.21 × 107). The highest number of copies of genotype IV in the urine was observed after six months (9.54 × 109), while the highest titer in the serum was not observed until after 12 months (3.88 × 106). DNAuria-BKPyV precedes BKPyV-DNAemia, affects a larger group of patients, and has a greater and more easily detected viral load, which makes it not only an earlier marker, but the key predictive marker of greater clinical value than later detection of BKPyV-DNAemia alone. Early monitoring of DNAuria-BKPyV should be the basis of classical screening, and not merely an addition to it, and therapeutic interventions should be undertaken early to prevent nephropathy.
- Open Access
- 12 August 2025
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 31, e947360
Electrocardiographic Indicators of Left Atrial Remodeling in Ischemic Stroke Patients with Atrial Fibrillation
BACKGROUND Left atrial (LA) remodeling (LAR) is a risk factor for atrial fibrillation (AF) and ischemic stroke (IS). LAR can be detected on electrocardiogram (ECG) by P wave indices. The aim of this study was to search for noninvasively assessed LAR markers associated with the history of IS in patients with AF, considering differences between males and females. MATERIAL AND METHODS This retrospective study included a group of 256 patients, aged 76.19 (±9.64) years, with documented AF and after IS. The control group consisted of 70 people aged 68.43 (±7.38) years with AF but without IS. The collected study material included ECG (longest P wave duration [Pmax], P wave duration [PWD], P wave dispersion [PWDI], P wave terminal force in lead V₁ [PWTFV₁], negative phase duration of the P in V₁ [PWDNV1]) and trans-thoracic echocardiography. Results were compared among both sexes and the control group. RESULTS In the study group, electrophysiological LAR was more advanced than in the control group, with significantly higher PWDI (80.60(±23.05) vs 62.49(±14.92) ms; p<0.001) and lower percentage of patients with normal Pmax/PWTFV1/PWDNV1/PWDI indices (2.73 vs 11.43%; p<0.05) respectively. LA area was larger (28.33(±7.50) vs 21.26(±2.79) cm²; p<0.001) and LVEF was lower (54.85(±9.14) vs 58.17(±6.40); p<0.05) in the study group compared to the control group. PWTF (4801.6(±3695.4) vs 4127.8(±3689.6) mcV*ms; p=0.049) was higher in males than in females. In multivariable logistic regression analysis, predictors significantly associated with IS occurrence in patients with AF were: higher PWDV₁ values (95% CI: 1.02-1.08, p<0.001), Pmax (95% CI: 0.90-0.97, p<0.001), and LVEF (95% CI: 0.84-0.99, p=0.030). CONCLUSIONS In patients with IS, higher indices of both structural and electrophysiological LAR are observed. There are significant differences between the sexes in the severity of LAR indices.
- 12 August 2025
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 31, e947360
Open AccessElectrocardiographic Indicators of Left Atrial Remodeling in Ischemic Stroke Patients with Atrial Fibrillation
BACKGROUND Left atrial (LA) remodeling (LAR) is a risk factor for atrial fibrillation (AF) and ischemic stroke (IS). LAR can be detected on electrocardiogram (ECG) by P wave indices. The aim of this study was to search for noninvasively assessed LAR markers associated with the history of IS in patients with AF, considering differences between males and females. MATERIAL AND METHODS This retrospective study included a group of 256 patients, aged 76.19 (±9.64) years, with documented AF and after IS. The control group consisted of 70 people aged 68.43 (±7.38) years with AF but without IS. The collected study material included ECG (longest P wave duration [Pmax], P wave duration [PWD], P wave dispersion [PWDI], P wave terminal force in lead V₁ [PWTFV₁], negative phase duration of the P in V₁ [PWDNV1]) and trans-thoracic echocardiography. Results were compared among both sexes and the control group. RESULTS In the study group, electrophysiological LAR was more advanced than in the control group, with significantly higher PWDI (80.60(±23.05) vs 62.49(±14.92) ms; p<0.001) and lower percentage of patients with normal Pmax/PWTFV1/PWDNV1/PWDI indices (2.73 vs 11.43%; p<0.05) respectively. LA area was larger (28.33(±7.50) vs 21.26(±2.79) cm²; p<0.001) and LVEF was lower (54.85(±9.14) vs 58.17(±6.40); p<0.05) in the study group compared to the control group. PWTF (4801.6(±3695.4) vs 4127.8(±3689.6) mcV*ms; p=0.049) was higher in males than in females. In multivariable logistic regression analysis, predictors significantly associated with IS occurrence in patients with AF were: higher PWDV₁ values (95% CI: 1.02-1.08, p<0.001), Pmax (95% CI: 0.90-0.97, p<0.001), and LVEF (95% CI: 0.84-0.99, p=0.030). CONCLUSIONS In patients with IS, higher indices of both structural and electrophysiological LAR are observed. There are significant differences between the sexes in the severity of LAR indices.
- Open Access
- 16 June 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (12) , 3526
The Influence of Balneotherapy Using Salty Sulfide–Hydrogen Sulfide Water on Selected Markers of the Cardiovascular System: A Prospective Study
Background: The sulfide–hydrogen sulfide brine balneotherapy (HSBB), including a combination of dissolved hydrogen sulfide (H2S) gas, inorganic sulfur ions (S2−), and hydrosulfide ions (HS−), is one of the most important and most effective forms of spa treatment in patients with osteoarticular disorders (OADs). Some cardiovascular diseases (CVDs) are often considered to be contraindications to HSBB since the presence of thiol groups may lead to an increased quantity of reactive oxygen species (ROS), which damage the vascular endothelium, and endothelial dysfunction is considered to be the main cause of atherosclerosis. However, there are a number of literature reports suggesting this theory to be false. H2S is a member of the endogenous gaseous transmitter family and, since it is a relatively recent addition, it has the least well-known biological properties. H2S–NO interactions play an important role in oxidative stress in CVDs. The general objective of this study was to assess the cardiovascular safety of HSBB and analyze the effect of HSBB on selected cardiovascular risk markers. Methods: A total of 100 patients at the age of 76.3 (±7.5) years from the Włókniarz Sanatorium in Busko-Zdrój were initially included in the study. The following parameters were assessed: age, sex, height, body weight, body surface area (BSA), body mass index (BMI), systolic (SBP) and diastolic blood pressure (DBP), heart rate, the diagnosis of OAD that was the indication for balneotherapy, creatinine (CREAT), glomerular filtration rate (GFR), lipid panel, C-reactive protein (CRP), uric acid (UA), and fibrinogen (FIBR) and cardiovascular markers: (cardiac troponin T (cTnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP). Results: A significant decrease in DBP and a trend towards SBP reduction were observed over the course of the study. A significant decrease was observed in CRP levels decreasing from 2.7 (±3.6) mg/L to 2.06 (±1.91) mg/L, whereas FIBR rose significantly from 2.95 (±0.59) g/L to 3.23 (±1.23) g/L. LDL-C levels decreased slightly, statistically significant, from 129.36 (±40.67) mg/dL to 123.74 (±36.14) mg/dL. HSBB did not affect the levels of evaluated cardiovascular biomarkers, namely NT-proBNP (137.41 (±176.52) pg/mL vs. 142.89 (±182.82) pg/mL; p = 0.477) and cTnT (9.64 (±4.13) vs. 9.65 (±3.91) ng/L; p = 0.948). A multiple regression analysis of pre-balneotherapy and post-balneotherapy values showed cTnT levels to be independently correlated only with CREAT levels and GFR values. None of the assessed parameters independently correlated with the NT-proBNP level. Conclusions: HSBB resulted in a statistically significant improvement in a subclinical pro-inflammatory state. HSBB has a beneficial effect in modifying key cardiovascular risk factors by reducing LDL-C levels and DBP values. HSBB has a neutral effect on cardiovascular ischemia/injury. Despite slightly elevated baseline levels of the biochemical marker of HF (NT-proBNP), HSBB causes no further increase in this marker. The use of HSBB in patients with OAD has either a neutral effect or a potentially beneficial effect on the cardiovascular system, which may constitute grounds for further studies to verify the current cardiovascular contraindications for this form of therapy.
- 16 June 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (12) , 3526
Open AccessThe Influence of Balneotherapy Using Salty Sulfide–Hydrogen Sulfide Water on Selected Markers of the Cardiovascular System: A Prospective Study
Background: The sulfide–hydrogen sulfide brine balneotherapy (HSBB), including a combination of dissolved hydrogen sulfide (H2S) gas, inorganic sulfur ions (S2−), and hydrosulfide ions (HS−), is one of the most important and most effective forms of spa treatment in patients with osteoarticular disorders (OADs). Some cardiovascular diseases (CVDs) are often considered to be contraindications to HSBB since the presence of thiol groups may lead to an increased quantity of reactive oxygen species (ROS), which damage the vascular endothelium, and endothelial dysfunction is considered to be the main cause of atherosclerosis. However, there are a number of literature reports suggesting this theory to be false. H2S is a member of the endogenous gaseous transmitter family and, since it is a relatively recent addition, it has the least well-known biological properties. H2S–NO interactions play an important role in oxidative stress in CVDs. The general objective of this study was to assess the cardiovascular safety of HSBB and analyze the effect of HSBB on selected cardiovascular risk markers. Methods: A total of 100 patients at the age of 76.3 (±7.5) years from the Włókniarz Sanatorium in Busko-Zdrój were initially included in the study. The following parameters were assessed: age, sex, height, body weight, body surface area (BSA), body mass index (BMI), systolic (SBP) and diastolic blood pressure (DBP), heart rate, the diagnosis of OAD that was the indication for balneotherapy, creatinine (CREAT), glomerular filtration rate (GFR), lipid panel, C-reactive protein (CRP), uric acid (UA), and fibrinogen (FIBR) and cardiovascular markers: (cardiac troponin T (cTnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP). Results: A significant decrease in DBP and a trend towards SBP reduction were observed over the course of the study. A significant decrease was observed in CRP levels decreasing from 2.7 (±3.6) mg/L to 2.06 (±1.91) mg/L, whereas FIBR rose significantly from 2.95 (±0.59) g/L to 3.23 (±1.23) g/L. LDL-C levels decreased slightly, statistically significant, from 129.36 (±40.67) mg/dL to 123.74 (±36.14) mg/dL. HSBB did not affect the levels of evaluated cardiovascular biomarkers, namely NT-proBNP (137.41 (±176.52) pg/mL vs. 142.89 (±182.82) pg/mL; p = 0.477) and cTnT (9.64 (±4.13) vs. 9.65 (±3.91) ng/L; p = 0.948). A multiple regression analysis of pre-balneotherapy and post-balneotherapy values showed cTnT levels to be independently correlated only with CREAT levels and GFR values. None of the assessed parameters independently correlated with the NT-proBNP level. Conclusions: HSBB resulted in a statistically significant improvement in a subclinical pro-inflammatory state. HSBB has a beneficial effect in modifying key cardiovascular risk factors by reducing LDL-C levels and DBP values. HSBB has a neutral effect on cardiovascular ischemia/injury. Despite slightly elevated baseline levels of the biochemical marker of HF (NT-proBNP), HSBB causes no further increase in this marker. The use of HSBB in patients with OAD has either a neutral effect or a potentially beneficial effect on the cardiovascular system, which may constitute grounds for further studies to verify the current cardiovascular contraindications for this form of therapy.
- Open Access
- 15 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 25 (4) , e144
Unusual dilemmas of a cardiologist—does congenital absence of the left atrial appendage really mean no indication for oral anticoagulation?
We present a case of a 72-year-old man with a history of recurrent atrial arrhythmias—paroxysmal atrial fibrillation (AF) and other comorbidities including hypertension, Type 2 diabetes, hypercholesterolaemia, and chronic kidney disease, anticoagulated with rivaroxaban (CHA2DS2-VASc score was 3), in whom several electrical cardioversion (EC) procedures were successfully performed in the past to restore sinus rhythm (SR). Due to the diagnosis of bradycardia-tachycardia syndrome, in April 2022, an atrio-ventricular sequential pacemaker was implanted. Because of the next AF episode exceeding 7 days and temporary break in the use of rivaroxaban anticoagulation, a transoesophageal echocardiography (TEE) before interventional treatment was performed. The examination showed a complete congenital absence of the left atrial appendage (LAA) (Panels E and F). Three-dimensional mapping of the right atrium (RA) was performed, identifying the focus of slowed conduction in the area of the posterior-inferior RA. Radiofrequency ablation of the arrhythmia substrate was performed. During the 3-month follow-up after ablation, the patient had two episodes of AF, each time effectively treated with short-term sedation EC. Despite the lack of LAA, the patient remained on anticoagulation (rivaroxaban) due to still existing strong clinical reasons for long-term anticoagulant treatment, namely three points in CHA2DS2-VASc, left atrium (LA) enlargement, and LA stunning phenomenon after AF reversion to SR. In the meantime, the patient’s myocardial imaging diagnostics was supplemented with a cardiac tomography, during which a congenital isolated absence of the LAA was confirmed (Panels A–D).
- 15 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 25 (4) , e144
Open AccessUnusual dilemmas of a cardiologist—does congenital absence of the left atrial appendage really mean no indication for oral anticoagulation?
We present a case of a 72-year-old man with a history of recurrent atrial arrhythmias—paroxysmal atrial fibrillation (AF) and other comorbidities including hypertension, Type 2 diabetes, hypercholesterolaemia, and chronic kidney disease, anticoagulated with rivaroxaban (CHA2DS2-VASc score was 3), in whom several electrical cardioversion (EC) procedures were successfully performed in the past to restore sinus rhythm (SR). Due to the diagnosis of bradycardia-tachycardia syndrome, in April 2022, an atrio-ventricular sequential pacemaker was implanted. Because of the next AF episode exceeding 7 days and temporary break in the use of rivaroxaban anticoagulation, a transoesophageal echocardiography (TEE) before interventional treatment was performed. The examination showed a complete congenital absence of the left atrial appendage (LAA) (Panels E and F). Three-dimensional mapping of the right atrium (RA) was performed, identifying the focus of slowed conduction in the area of the posterior-inferior RA. Radiofrequency ablation of the arrhythmia substrate was performed. During the 3-month follow-up after ablation, the patient had two episodes of AF, each time effectively treated with short-term sedation EC. Despite the lack of LAA, the patient remained on anticoagulation (rivaroxaban) due to still existing strong clinical reasons for long-term anticoagulant treatment, namely three points in CHA2DS2-VASc, left atrium (LA) enlargement, and LA stunning phenomenon after AF reversion to SR. In the meantime, the patient’s myocardial imaging diagnostics was supplemented with a cardiac tomography, during which a congenital isolated absence of the LAA was confirmed (Panels A–D).
- Open Access
- 15 August 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (16) , 9173
Genotypes and Variants of BKPyV in Organ Donors after Brain Death
Kidney transplantation from a donor with latent BKPyV might be the cause of serious complications, such as BK virus-associated nephropathy. The aim of the study was to determine the prevalence of BKPyV infection in donors after brain death (DBDs), to analyse the molecular variation of BKPyV and to compare clinical and inflammation parameters of DBDs infected with various genotypes of BKPyV. BKPyV was investigated in blood and urine samples of 103 DBDs using PCR followed by sequencing and bioinformatic analysis, and the viral load was assessed by qPCR. Clinical parameters, including cellular markers of inflammation were assessed. The results confirm high prevalence of BKPyV (48%),and genotype IV (49%) over genotype I (43%) and the co-infection with genotypes I and IV in 8.2%. Viral load ranged from 102 to 107 copies/mL, with an average of 1.92 × 106 copies/mL. No specific markers for BKPyV infection were detected among the parameters tested. Infection with genotype I may be associated with the adverse impact on thekidney function, while infection with genotype IV was associated with the anemia Not only the viral load but also the genotype of BKPyV may have an impact on the course of infection.
- 15 August 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (16) , 9173
Open AccessGenotypes and Variants of BKPyV in Organ Donors after Brain Death
Kidney transplantation from a donor with latent BKPyV might be the cause of serious complications, such as BK virus-associated nephropathy. The aim of the study was to determine the prevalence of BKPyV infection in donors after brain death (DBDs), to analyse the molecular variation of BKPyV and to compare clinical and inflammation parameters of DBDs infected with various genotypes of BKPyV. BKPyV was investigated in blood and urine samples of 103 DBDs using PCR followed by sequencing and bioinformatic analysis, and the viral load was assessed by qPCR. Clinical parameters, including cellular markers of inflammation were assessed. The results confirm high prevalence of BKPyV (48%),and genotype IV (49%) over genotype I (43%) and the co-infection with genotypes I and IV in 8.2%. Viral load ranged from 102 to 107 copies/mL, with an average of 1.92 × 106 copies/mL. No specific markers for BKPyV infection were detected among the parameters tested. Infection with genotype I may be associated with the adverse impact on thekidney function, while infection with genotype IV was associated with the anemia Not only the viral load but also the genotype of BKPyV may have an impact on the course of infection.
- Open Access
Molecular Epidemiology and Variation of the BK Polyomavirus in the Population of Central and Eastern Europe Based on the Example of Poland
The BK polyomavirus (BKPyV) is a widespread pathogen in humans. Polymorphism of the region encoding the VP1 protein of BKPyV provides the basis for classifying the virus into types and subtypes, whose frequency varies depending on geographic location. The aim of our study was to determine the frequency of BKPyV in the Polish population and to assess its variation by analysing polymorphism in the typing region. The study was conducted on 168 healthy, Polish volunteers, whose blood (plasma) and urine were sampled. The virus was detected using PCR, products, sequenced and subjected to bioinformatic analysis. In addition, viral load was assessed by qPCR. The presence of the genetic material of the BK virus was noted in 61/168 urine samples but in none of the plasma sample. Sequencing and phylogenetic analysis confirmed that the BKPyV isolates were of types I and IV, dominant in Europe (63.93% and 36.07%, respectively). All isolates from genotype I belonged to subtype Ib-2, showing polymorphism at position 1809 with a frequency of 61.54% (G1809A) and 38.46% (G1809C). To the best of our knowledge, this is the first study of this magnitude on the genetic variation of BKPyV among healthy volunteers in Poland.
Open AccessMolecular Epidemiology and Variation of the BK Polyomavirus in the Population of Central and Eastern Europe Based on the Example of Poland
The BK polyomavirus (BKPyV) is a widespread pathogen in humans. Polymorphism of the region encoding the VP1 protein of BKPyV provides the basis for classifying the virus into types and subtypes, whose frequency varies depending on geographic location. The aim of our study was to determine the frequency of BKPyV in the Polish population and to assess its variation by analysing polymorphism in the typing region. The study was conducted on 168 healthy, Polish volunteers, whose blood (plasma) and urine were sampled. The virus was detected using PCR, products, sequenced and subjected to bioinformatic analysis. In addition, viral load was assessed by qPCR. The presence of the genetic material of the BK virus was noted in 61/168 urine samples but in none of the plasma sample. Sequencing and phylogenetic analysis confirmed that the BKPyV isolates were of types I and IV, dominant in Europe (63.93% and 36.07%, respectively). All isolates from genotype I belonged to subtype Ib-2, showing polymorphism at position 1809 with a frequency of 61.54% (G1809A) and 38.46% (G1809C). To the best of our knowledge, this is the first study of this magnitude on the genetic variation of BKPyV among healthy volunteers in Poland.
- Open Access
BK Polyomavirus—Biology, Genomic Variation and Diagnosis
The BK polyomavirus (BKPyV), a representative of the family Polyomaviridae, is widespread in the human population. While the virus does not cause significant clinical symptoms in immunocompetent individuals, it is activated in cases of immune deficiency, both pharmacological and pathological. Infection with the BKPyV is of particular importance in recipients of kidney transplants or HSC transplantation, in which it can lead to the loss of the transplanted kidney or to haemorrhagic cystitis, respectively. Four main genotypes of the virus are distinguished on the basis of molecular differentiation. The most common genotype worldwide is genotype I, with a frequency of about 80%, followed by genotype IV (about 15%), while genotypes II and III are isolated only sporadically. The distribution of the molecular variants of the virus is associated with the region of origin. BKPyV subtype Ia is most common in Africa, Ib-1 in Southeast Asia, and Ib-2 in Europe, while Ic is the most common variant in Northeast Asia. The development of molecular methods has enabled significant improvement not only in BKPyV diagnostics, but in monitoring the effectiveness of treatment as well. Amplification of viral DNA from urine by PCR (Polymerase Chain Reaction) and qPCR Quantitative Polymerase Chain Reaction) is a non-invasive method that can be used to confirm the presence of the genetic material of the virus and to determine the viral load. Sequencing techniques together with bioinformatics tools and databases can be used to determine variants of the virus, analyse their circulation in populations, identify relationships between them, and investigate the directions of evolution of the virus.
Open AccessBK Polyomavirus—Biology, Genomic Variation and Diagnosis
The BK polyomavirus (BKPyV), a representative of the family Polyomaviridae, is widespread in the human population. While the virus does not cause significant clinical symptoms in immunocompetent individuals, it is activated in cases of immune deficiency, both pharmacological and pathological. Infection with the BKPyV is of particular importance in recipients of kidney transplants or HSC transplantation, in which it can lead to the loss of the transplanted kidney or to haemorrhagic cystitis, respectively. Four main genotypes of the virus are distinguished on the basis of molecular differentiation. The most common genotype worldwide is genotype I, with a frequency of about 80%, followed by genotype IV (about 15%), while genotypes II and III are isolated only sporadically. The distribution of the molecular variants of the virus is associated with the region of origin. BKPyV subtype Ia is most common in Africa, Ib-1 in Southeast Asia, and Ib-2 in Europe, while Ic is the most common variant in Northeast Asia. The development of molecular methods has enabled significant improvement not only in BKPyV diagnostics, but in monitoring the effectiveness of treatment as well. Amplification of viral DNA from urine by PCR (Polymerase Chain Reaction) and qPCR Quantitative Polymerase Chain Reaction) is a non-invasive method that can be used to confirm the presence of the genetic material of the virus and to determine the viral load. Sequencing techniques together with bioinformatics tools and databases can be used to determine variants of the virus, analyse their circulation in populations, identify relationships between them, and investigate the directions of evolution of the virus.
- Open Access
Heat Shock Protein 27 Is an Emerging Predictor of Contrast-Induced Acute Kidney Injury on Patients Subjected to Percutaneous Coronary Interventions
Contrast-induced acute kidney injury (CI-AKI) is a serious complication associated with considerable morbidity and mortality. Heat-shock protein 27 (HSP27) plays a role in the defense of the kidney tissue against various forms of cellular stress, including hypoxia and oxydative stress, both features associated with CI-AKI. The aim of our study was to evaluate a potential predictive value of HSP27 for CI-AKI in patients subjected to percutaneous coronary interventions (PCI). Included were 343 selected patients subjected to PCI. Exclusion criteria were conditions that potentially might influence HSP27 levels. HSP27 serum levels were evaluated prior to PCI, together with serum creatinine, the concentration of which was also evaluated twice at 48 and 72 h post PCI. CI-AKI was diagnosed in 9.3% of patients. Patients in whom CI-AKI was diagnosed were older (p < 0.001), were more often females (p = 0.021), had higher prevalence of diabetes (p = 0.011), hypotension during PCI (p < 0.001), albuminuria (p = 0.004) as well as multivessel disease (p = 0.002), received higher contrast volume (p = 0.006), more often received contrast volume (CV) above the maximum allowed contrast dose (MACD) (p < 0.001), and had lower HSP27 level (p < 0.001). On multivariate analysis, CV > MACD (OR 1.23, p = 0.001), number of diseased vessels (OR 1.27, p = 0.006), and HSP27 (OR 0.81, p = 0.001) remained independent predictors of CI-AKI. Low concentration of HSP27 is an emerging, strong and independent predictor of CI-AKI in patients subjected to PCI.
Open AccessHeat Shock Protein 27 Is an Emerging Predictor of Contrast-Induced Acute Kidney Injury on Patients Subjected to Percutaneous Coronary Interventions
Contrast-induced acute kidney injury (CI-AKI) is a serious complication associated with considerable morbidity and mortality. Heat-shock protein 27 (HSP27) plays a role in the defense of the kidney tissue against various forms of cellular stress, including hypoxia and oxydative stress, both features associated with CI-AKI. The aim of our study was to evaluate a potential predictive value of HSP27 for CI-AKI in patients subjected to percutaneous coronary interventions (PCI). Included were 343 selected patients subjected to PCI. Exclusion criteria were conditions that potentially might influence HSP27 levels. HSP27 serum levels were evaluated prior to PCI, together with serum creatinine, the concentration of which was also evaluated twice at 48 and 72 h post PCI. CI-AKI was diagnosed in 9.3% of patients. Patients in whom CI-AKI was diagnosed were older (p < 0.001), were more often females (p = 0.021), had higher prevalence of diabetes (p = 0.011), hypotension during PCI (p < 0.001), albuminuria (p = 0.004) as well as multivessel disease (p = 0.002), received higher contrast volume (p = 0.006), more often received contrast volume (CV) above the maximum allowed contrast dose (MACD) (p < 0.001), and had lower HSP27 level (p < 0.001). On multivariate analysis, CV > MACD (OR 1.23, p = 0.001), number of diseased vessels (OR 1.27, p = 0.006), and HSP27 (OR 0.81, p = 0.001) remained independent predictors of CI-AKI. Low concentration of HSP27 is an emerging, strong and independent predictor of CI-AKI in patients subjected to PCI.
- Open Access
Atypical Cardiac Location of Melanoma of Unknown Origin
The subject was a 66-year-old woman, suffering from the chest pain evoked by physical activity. Transthoracic echocardiography (TTE) revealed an abnormal structure, 41 × 29 mm. In MSCT, a hypodensic mobile tissue lesion that was infiltrating the whole thickness of left ventricle was confirmed. PET excluded the existence of other remote lesions. After surgical tumor removal, histopathological differential diagnosis revealed melanoma, myoepithelial cancer, and MPNST “high–grade” sarcoma. A control TTE detected a tumor that was 14 × 10 mm. After immunohistochemical results, immunotherapy with pembrolizumab was used, which resulted in complete tumor resolution. Presently, surgical resection and neoadjuvant targeted immunochemotherapy remain the treatment of choice for clinical stage III/IV melanoma.
Open AccessAtypical Cardiac Location of Melanoma of Unknown Origin
The subject was a 66-year-old woman, suffering from the chest pain evoked by physical activity. Transthoracic echocardiography (TTE) revealed an abnormal structure, 41 × 29 mm. In MSCT, a hypodensic mobile tissue lesion that was infiltrating the whole thickness of left ventricle was confirmed. PET excluded the existence of other remote lesions. After surgical tumor removal, histopathological differential diagnosis revealed melanoma, myoepithelial cancer, and MPNST “high–grade” sarcoma. A control TTE detected a tumor that was 14 × 10 mm. After immunohistochemical results, immunotherapy with pembrolizumab was used, which resulted in complete tumor resolution. Presently, surgical resection and neoadjuvant targeted immunochemotherapy remain the treatment of choice for clinical stage III/IV melanoma.
- 25 September 2020
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 78 (9) , 943-944
Septic cerebral stroke associated with infective endocarditis after the MitraClip procedure
DOI: 10.33963/KP.15481, Published online: July 06, 2020, Authors: Tomasz Zapolski, Agnieszka Styczeń, Mariusz Kozak, Marta Karaś-Głodek, Wojciech Brzozowski, Andrzej Tomaszewski, Andrzej Wysokiński
- 25 September 2020
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 78 (9) , 943-944
Septic cerebral stroke associated with infective endocarditis after the MitraClip procedure
DOI: 10.33963/KP.15481, Published online: July 06, 2020, Authors: Tomasz Zapolski, Agnieszka Styczeń, Mariusz Kozak, Marta Karaś-Głodek, Wojciech Brzozowski, Andrzej Tomaszewski, Andrzej Wysokiński